Abstract
The p38 mitogen activated protein (MAP) kinase is an integral enzyme involved in the production of a wide variety of pro-inflammatory cytokines from various cell types. The identification of this kinase and of the diaryl imidazole containing inhibitor, SB203580, initiated an intense discovery effort in this field. Numerous inhibitors were subsequently produced containing replacements for the imidazole, as well as some of the pharmacophores attached to it. During this time many other classes of potent p38 inhibitors emerged containing scaffolds and binding components not found in the diaryl imidazole group. This review summarizes nine of those classes. At least one of these classes requires the kinase to undergo reorganization prior to binding. From this diverse set of inhibitors four compounds have been reported advancing into human clinical trials.
Keywords: kinase inhibition, anti-cancer agents, purine-derived compounds, cell cycle, solid phase synthesis, biological activity
Current Topics in Medicinal Chemistry
Title: The Non-Diaryl Heterocycle Classes of p38 MAP Kinase Inhibitors
Volume: 2 Issue: 9
Author(s): Pier F. Cirillo, Christopher Pargellis and John Regan
Affiliation:
Keywords: kinase inhibition, anti-cancer agents, purine-derived compounds, cell cycle, solid phase synthesis, biological activity
Abstract: The p38 mitogen activated protein (MAP) kinase is an integral enzyme involved in the production of a wide variety of pro-inflammatory cytokines from various cell types. The identification of this kinase and of the diaryl imidazole containing inhibitor, SB203580, initiated an intense discovery effort in this field. Numerous inhibitors were subsequently produced containing replacements for the imidazole, as well as some of the pharmacophores attached to it. During this time many other classes of potent p38 inhibitors emerged containing scaffolds and binding components not found in the diaryl imidazole group. This review summarizes nine of those classes. At least one of these classes requires the kinase to undergo reorganization prior to binding. From this diverse set of inhibitors four compounds have been reported advancing into human clinical trials.
Export Options
About this article
Cite this article as:
Cirillo F. Pier, Pargellis Christopher and Regan John, The Non-Diaryl Heterocycle Classes of p38 MAP Kinase Inhibitors, Current Topics in Medicinal Chemistry 2002; 2 (9) . https://dx.doi.org/10.2174/1568026023393390
DOI https://dx.doi.org/10.2174/1568026023393390 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Prognostic Value of Copeptin in Chronic Kidney Disease: From General Population to End-Stage Renal Disease
Current Protein & Peptide Science Editorial from Guest Editors [Hot Topic: Viral Bronchiolitis: The Year in Review (Guest Editors: Louis Bont and Jan Kimpen)]
Current Respiratory Medicine Reviews Meet Our Associate Editor
Current Bioinformatics Aldose Reductase in Diabetic Microvascular Complications
Current Drug Targets HELLP Syndrome: Pathophysiology and Current Therapies
Current Pharmaceutical Biotechnology Kappa Opioids, Salvinorin A and Major Depressive Disorder
Current Neuropharmacology Administration of Human Umbilical Cord Blood Cells Produces Interleukin-10 (IL-10) in IL-10 Deficient Mice Without Immunosuppression
Current Stem Cell Research & Therapy Regulation of Neutrophil Apoptosis and Removal of Apoptotic Cells
Current Drug Targets - Inflammation & Allergy Adenovirus Mediated Herpes Simplex Virus-Thymidine Kinase/Ganciclovir Gene Therapy for Resectable Malignant Glioma
Current Gene Therapy Development of Multifunctional Nanoparticles for Targeted Drug Delivery and Noninvasive Imaging of Therapeutic Effect
Current Drug Discovery Technologies The Role of Epithelial-Mesenchymal Interactions in Tissue Repair, Fibrogenesis and Carcinogenesis
Current Signal Transduction Therapy Transforming Mutations of Jak3 (A573V and M511I) Show Differential Sensitivity to Selective Jak3 Inhibitors
Clinical Cancer Drugs Targeting the Tumor Proteasome as a Mechanism to Control the Synthesis and Bioactivity of Matrix Macromolecules
Current Molecular Medicine Importance and Limitations of Chemotherapy Among the Available Treatments for Gastrointestinal Tumours
Anti-Cancer Agents in Medicinal Chemistry Urinary Cytokines as Biomarkers in Glomerular Diseases
Recent Patents on Biomarkers Monoclonal Antibodies Against Epidermal Growth Factor Receptor in Advanced Colorectal Carcinoma: Clinical Efficacy and Markers of Sensitivity&#
Reviews on Recent Clinical Trials Association between Antiretroviral Treatment and Markers of Systemic Inflammation among HIV Patients in Ghana
Current HIV Research Src Family Kinases as Potential Therapeutic Targets for Malignancies and Immunological Disorders
Current Medicinal Chemistry The ‘Other’ Telomerase Inhibitors: Non-G-Quadruplex Interactive Agent, Non-Antisense, Non-Reverse Transcriptase Telomerase Inhibitors
Current Medicinal Chemistry - Anti-Cancer Agents Editorial [Hot Topic: Spinal Cord Injury and Repair - Part I (Executive Editor: Weihong Pan)]
Current Pharmaceutical Design